Your browser doesn't support javascript.
loading
Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group.
Kaplan, Muhammet Ali; Sendur, Mehmet Ali Nahit; Cangir, Ayten Kayi; Firat, Pinar; Göker, Erdem; Kiliçkap, Saadettin; Oyan, Basak; Büge Öz, Aysim; Özdemir, Feyyaz; Özyigit, Gökhan.
Affiliation
  • Kaplan MA; Department of Medical Oncology, Dicle University Hospitals Faculty of Medicine, Diyarbakir, Turkey. Electronic address: drmalikaplan@hotmail.com.
  • Sendur MAN; Department of Medical Oncology, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey.
  • Cangir AK; Department of Thoracic Surgery, Ankara University Faculty of Medicine, Ibni Sina Hospital, Ankara, Turkey.
  • Firat P; Department of Pathology, Koc University School of Medicine, Istanbul, Turkey.
  • Göker E; Department of Medical Oncology, Ege University Faculty of Medicine, Izmir, Turkey.
  • Kiliçkap S; Department of Medical Oncology, Liv Hospital Ankara, Ankara, Turkey; Department of Medical Oncology, Istinye University Faculty of Medicine, Istanbul, Turkey.
  • Oyan B; Department of Medical Oncology, Acibadem University Faculty of Medicine, Istanbul, Turkey.
  • Büge Öz A; Department of Medical Pathology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey.
  • Özdemir F; Department of Medical Oncology, Karadeniz Technical University, Trabzon, Turkey.
  • Özyigit G; Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Curr Probl Cancer ; 47(6): 101017, 2023 Dec.
Article de En | MEDLINE | ID: mdl-37845104
ABSTRACT
Pleural mesothelioma (PM) is a cancer of the pleural surface, which is aggressive and may be rapidly fatal. PM is a rare cancer worldwide, but is a relatively common disease in Turkey. Asbestos exposure is the main risk factor and the most common underlying cause of the disease. There have been significant improvements in diagnoses and treatments of many malignancies; however, there are still therapeutic challenges in PM. In this review, we aimed to increase the awareness of health care professionals, oncologists, and pulmonologists by underlining the unmet needs of patients with PM and by emphasizing the need for a multidisciplinary treatment and management of PM. After reviewing the general information about PM, we further discuss the treatment options for patients with PM using immunotherapy and offer evidence for improvements in the clinical outcomes of these patients because of these newer treatment modalities.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de la plèvre / Mésothéliome Limites: Humans Pays/Région comme sujet: Asia Langue: En Journal: Curr Probl Cancer Année: 2023 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de la plèvre / Mésothéliome Limites: Humans Pays/Région comme sujet: Asia Langue: En Journal: Curr Probl Cancer Année: 2023 Type de document: Article